Last reviewed · How we verify
NCT06222164
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
trial in Hematologic Diseases in 2,000 participants. Currently enrolling.
30 March 2027
Quick facts
| Lead sponsor | Invivoscribe, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 30 March 2024 |
| Primary completion | 30 March 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Conditions studied
- Hematologic Diseases — all drugs for Hematologic Diseases →
Sponsor
Invivoscribe, Inc.
Who can join
18 and older, any sex, with Hematologic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06222164
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Diseases
Currently open trials in the same condition.
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT05414045 — Autologous Testicular Tissue Transplantation · NA · recruiting
- NCT06613425 — Clinical Study of Combined Platelet Transfusion · Phase 4 · recruiting
- NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting
Other Invivoscribe, Inc. trials
Trials by the same sponsor.
- NCT06876571 — Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay · not yet recruiting
- NCT06112301 — Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay · completed
- NCT04391400 — The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intend · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06222164 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Invivoscribe, Inc.
- Last refreshed: 4 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06222164.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing